Related Experiment Videos
[Radiosensitization by hypoxic cell radiosensitizer--present status of radiosensitizer]
1Dept. of Radiation Oncology School of Med., Tokai Univ.
Abstract:
Because of the unsuccessful clinical trials of misonidazole (MISO), many efforts have been made to find a new hypoxic cell sensitizer which is more effective and/or less toxic than MISO. In Japan, RK-28 is already under going Phase II clinical evaluation and RP-170, KU-2285 and KIH-802 have been proven to be effective both in vitro and in vivo and are also waiting further clinical trials. But in U.S.A. and England, etanidazole (SR-2508) and pimonidazole (Ro 03-8799) are under going Phase III evaluation and clinical evaluation of SR-2508 will be key opened in early next year. Now, an appropriate goal for a new radiosensitizer would be more effective and/or less toxic than SR-2508 or clinically more useful than SR-2508. Clinical trials of SR-2508 have been performed using intravenous injection, however it may be difficult to give a sensitizer intravenously on a daily basis in accordance with requirements for standard fractionated radiotherapy in a clinical setting. In contrast, RP-170 and KU-2285 have the potential to produce considerable radiosensitization under both intravenous and oral administration.
Insights
New hypoxic cell sensitizers are being developed to improve upon misonidazole. RP-170 and KU-2285 show promise for radiosensitization via oral or intravenous administration.
Area of Science:
- Oncology
- Radiotherapy
- Pharmacology
Context:
- Misonidazole (MISO) clinical trials were unsuccessful, necessitating new hypoxic cell sensitizers.
- Current research focuses on developing agents with improved efficacy and reduced toxicity compared to MISO.
- Several novel radiosensitizers, including RK-28, RP-170, KU-2285, and KIH-802, are under investigation in Japan.
Purpose:
- To identify and evaluate novel hypoxic cell sensitizers that are more effective and/or less toxic than existing agents.
- To compare the clinical utility of new radiosensitizers against etanidazole (SR-2508) and pimonidazole (Ro 03-8799).
- To explore radiosensitizers with administration routes suitable for standard fractionated radiotherapy.
Summary:
- Etanidazole (SR-2508) and pimonidazole (Ro 03-8799) are in Phase III clinical evaluation in the US and UK.
- A key goal is to find radiosensitizers superior to SR-2508 in efficacy, toxicity, or clinical applicability.
- RP-170 and KU-2285 demonstrate potential for significant radiosensitization through both intravenous and oral administration, offering greater clinical flexibility.
Impact:
- Development of more effective and safer radiosensitizers for cancer treatment.
- Improved patient outcomes through enhanced radiotherapy efficacy.
- Potential for more convenient and adaptable radiotherapy regimens with orally administered sensitizers.